Showing 6251-6260 of 9745 results for "".
- US FDA Grants Dupixent Priority Review for Moderate-to-Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-grants-dupixent-priority-review-for-moderate-to-severe-ad-in-adolescents/2457517/The US Food and Drug Administration (FDA) has granted Priority Review for Dupixent (dupilumab) as a potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis (AD). Currently, there are no FDA-approved systemic biologic medicines to treat adolescents with m
- Researchers Identify Genes Involved in Skin Cancerhttps://practicaldermatology.com/news/researchers-identify-genes-involved-in-skin-cancer/2457528/Researchers at the Health Sciences department of the Universitat Jaume I (UJI) of Castellón, Spain, have identified the genes responsible for sun sensitivity and skin cancer vulnerability. The Skin Cancer Genetics and Human Pigmentation research group (Melanogén) has analysed the sk
- LA BioMed Team to Study Treatments for Antibiotic-Resistant Skin Infectionshttps://practicaldermatology.com/news/la-biomed-team-to-study-treatments-for-antibiotic-resistant-skin-infections/2457533/Investigators from LA BioMed have scored a $5.3M grant from the National Institutes of Health to study the effectiveness of treatments for antibiotic-resistant skin infections. The study,
- Scott Peterson, PhD to Head Medical Affairs at Evolushttps://practicaldermatology.com/news/scott-peterson-phd-to-head-medical-affairs-at-evolus/2457535/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti
- Opdivo Plus Yervoy Demonstrates Durable Four-Year Survival Benefits in Advanced Melanomahttps://practicaldermatology.com/news/opdivo-plus-yervoy-demonstrates-durable-four-year-survival-benefits-in-advanced-melanoma/2457552/Four-year data from the Phase 3 CheckMate-067 clinical trial—the longest follow-up to date—continue to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in
- New from xMedica: Aesthetics Conference Features Energy Based Treatments for Male and Female Sexual Wellnesshttps://practicaldermatology.com/news/new-from-xmedica-aesthetics-conference-features-energy-based-treatments-for-male-and-female-sexual-wellness/2457553/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- Residents of Distinction Attend 2018 Coastal Dermatology Symposiumhttps://practicaldermatology.com/news/residents-of-distinction-attend-2018-coastal-dermatology-symposium/2457554/As part of the dermMentors Resident of Distinction Award program, sponsored by Beiersdorf Inc., five dermatology residents attended the 14th Annual Coastal Dermatology Symposium, held in Monterey, CA October 3-6, 2018. The 2018 dermMentors™
- Paradigm Shift: Cancer Patients Can Now Use Skin Creams During Radiation Therapyhttps://practicaldermatology.com/news/paradigm-shift-cancer-patients-can-now-use-skin-creams-during-radiation-therapy/2457556/Contrary to the advice most cancer patients receive when they go through radiation treatment, topical skin treatments, unless applied very heavily, do not increase the radiation dose to the skin and can be used in moderation before daily radiation treatments, according to a new study from the
- Psoriasis Plus Hypertension Equals Greater Need for Heart Surgeryhttps://practicaldermatology.com/news/psoriasis-plus-hypertension-equals-greater-need-for-cardiovascular-interventions/2457559/Patients with psoriasis and hypertension need more cardiovascular procedures and surgeries than hypertensive patients without psoriasis, a new study in the Journal of Dermatology suggests. In 5.62 year
- Real-world Evaluation Study Confirms Benefits of ARTAS iX Robotic Hair Restoration Systemhttps://practicaldermatology.com/news/real-world-evaluation-study-confirms-benefits-of-artas-ix-robotic-hair-restoration-system/2457560/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study. The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implanta